The Asia Pacific point of care diagnostics market size was valued at USD 8.17 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 8.1% from 2023 to 2030. The Asia Pacific region has seen significant growth in the point-of-care diagnostics market owing to factors such as rising healthcare expenditure, increased awareness about early disease detection, and the need for rapid and accurate diagnostic results.
The market is driven by four major factors namely growing geriatric population base in countries such as Japan and China, rising prevalence of target diseases, increasing demand for home healthcare, and introducing new products with technological advantages. Additionally, the growing prevalence of target diseases such as cancer, diabetes, cardiovascular diseases, and infectious diseases is expected to drive market growth over the forecast period.
Cardiovascular diseases are one of the most fatal disorders and are the leading cause of death across the globe. The high presence of unmet medical needs pertaining to this disease and the subsequent rise observed in patient awareness in the Asia Pacific region is expected to boost the demand for point of care (PoC) diagnostics. Moreover, the prevalence of diabetes in the Asia Pacific region is also on a constant rise, thus generating a wide patient base for the point of care glucose testing market.
The growing demand for home healthcare as a result of government initiatives and rising patient awareness aimed at reducing hospital stays and expenses associated with it is expected to boost the market growth in the region. On account of the growing demand for home healthcare, manufacturers such as F. Hoffmann-La Roche Ltd. and Abbott have introduced portable products which are user-friendly and therefore can be easily adopted by a patient. Decentralization of healthcare establishments as a cost-effective tool is a major trend observed in the overall PoC diagnostics market. Divisions such as emergency rooms, operating rooms, ICUs, cath labs, and neonatal intensive care units need point of care diagnostic solutions in order to implement rapid and effective patient care.
The Asia Pacific region is witnessing a notable upsurge in the prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and infectious diseases. PoC diagnostics have emerged as valuable tools for prompt detection and monitoring of these conditions, thereby enhancing disease management outcomes. Across the region, various countries are making significant investments in enhancing their healthcare infrastructure, particularly in remote and rural areas. Point-of-care diagnostics play a pivotal role in extending healthcare access to underserved populations by facilitating rapid and decentralized testing. Furthermore, there is a growing emphasis on the early detection and prevention of diseases throughout the Asia Pacific region. By enabling early diagnosis, point-of-care diagnostics contribute to timely treatment interventions, leading to improved patient outcomes.
Technological developments have helped in the development of innovative POC diagnostics solutions and services to increase efficiency. For instance, portable ultrasonography is mostly termed as a simple test, additionally, pulse oximetry test is a quick, simple, and affordable option among the various tests. The objective of the point of care is to bring simplicity and convenience to the patient. Point of care testing is often obtained through the use of potable instruments such as nerve conduction study device, blood glucose meter, and test kits including HIV salivary assay, Homocysteine, HBA1C, and CRP. The main goal of the point of care testing is collecting the specimen and obtaining the result in a very short period of time before the patient leaves.
The Asia Pacific region experienced a notable surge in the demand for COVID-19 testing during the pandemic. Point-of-care diagnostics, including rapid antigen tests and molecular diagnostic devices, played a critical role in delivering prompt and convenient testing solutions. These tests were mainly targeted towards blood, saliva, urine, and tears in which saliva in particular offered sufficient high detection rates in tandem with non-invasive and user-friendly procedures. The necessity for rapid and on-site testing to facilitate effective containment measures drove the widespread adoption of point-of-care testing methods. In response to the pandemic, a considerable number of manufacturers focused their efforts on developing and commercializing point-of-care COVID-19 testing solutions. These tests offered faster turnaround times and decreased reliance on centralized laboratories, thereby enabling the swift identification of infected individuals and contributing to infection control measures. To expedite the availability of point-of-care diagnostic tests for COVID-19, regulatory authorities in several countries implemented accelerated approval processes. These measures facilitated the rapid introduction of new products to the market, effectively meeting the heightened demand for testing.
The infectious diseases segment dominated the market with the highest revenue share in 2022 owing to the increasing adoption of point of care diagnostics as a substitute for traditional laboratory testing in infectious diseases applications. In addition, the increasing prevalence of infectious diseases such as fungal infections, parasitic infections, transmissible spongiform encephalopathies, bacterial infections, and viral infections in the Asia Pacific region is expected to further boost market growth.
The cancer markers segment is expected to grow at the fastest CAGR over the forecast period from 2023 to 2030. The Asia Pacific region has experienced a notable rise in the prevalence of cancer in recent years. This upward trend can be attributed to factors such as demographic shifts, including aging populations, as well as changes in lifestyle and environmental conditions. Consequently, these factors are expected to boost the demand for cancer markets in the region over the forecast period. Additionally, governments in the Asia Pacific region are placing a growing emphasis on cancer control and prevention. They are actively implementing awareness campaigns and screening programs to promote the early detection of cancer. Point-of-care diagnostics for cancer markers are acknowledged as valuable assets, thus generating an increased demand for these tests.
The clinics segment held the largest revenue share of over 35% in 2022. Clinics are essential in providing healthcare services, particularly in remote and underserved areas. Point-of-care diagnostics allow clinics to provide immediate testing and diagnosis without requiring samples to be sent to centralized laboratories. This improves patients' access to timely and efficient healthcare in these areas. In the Asia Pacific region, infectious diseases such as respiratory infections and sexually transmitted infections pose significant challenges. Point-of-care diagnostics aid in the rapid identification and control of infectious diseases within clinics, allowing for timely treatment and prevention.
The home point of care diagnostics segment is expected to grow at the fastest CAGR of 8.9% over the forecast period from 2023 to 2030. The COVID-19 pandemic had a significant impact on the demand for home PoC diagnostics. Consumer behavior increasingly shifted towards home-based testing options using point-of-care diagnostics for various conditions, including COVID-19, due to the need for social distancing and reducing exposure to crowded healthcare settings. Additionally, technology advancements have made home testing with point-of-care diagnostics more accessible, accurate, and user-friendly. Devices and test kits are becoming more user-friendly, requiring little training to perform accurate tests at home.
China dominated the Asia Pacific PoC diagnostics market with a revenue share of over 40% in 2022.China has the world's largest population and faces notable challenges related to the prevalence of chronic and infectious diseases within its borders resulting in an increasing demand for point-of-care diagnostics. Furthermore, China's aging population has contributed to an elevated incidence of chronic ailments like cardiovascular diseases, diabetes, and cancer. Point-of-care diagnostics serve as a crucial tool in effectively managing such conditions by enabling early detection, regular monitoring, and timely intervention.
India is expected to grow at the fastest CAGR of 9.2% over the forecast period from 2023 to 2030. A large population, healthcare needs, infectious disease prevalence, chronic disease burden, rural healthcare accessibility challenges, government initiatives, and technological advancements have all contributed to increased demand for point-of-care diagnostics in India. The demand for these diagnostics is expected to rise further in the future as the country continues to focus on improving healthcare infrastructure and addressing healthcare disparities.
The point of care diagnostics market in the Asia-pacific has so many different competitors which are mainly focused on developing innovative diagnostics technologies and expanding their geographical reach to capture the largest share of the market. These key players are mainly focused on developing innovative technologies, expanding their product portfolio, and increasing their geographical reach to capture a larger share in the market. Some of the major participants in the Asia Pacific point of care diagnostics market include:
Laipac Technology Inc.
Gauss Surgical, Inc.
Oxford Immune Algorithmics Ltd
F. Hoffmann-La Roche Ltd.
Beckman Coulter, Inc.
Radiometer Medical ApS
BD (Becton, Dickinson and Company)
Siemens Healthcare GmbH
Zoetis Services LLC
Instrumentation Laboratory Company
Trividia Health, Inc.
Orasure Technologies, Inc.
Nipro Europe Group Companies
Spectral Medical Inc.
Market size value in 2023
USD 9.04 billion
Revenue forecast in 2030
USD 15.61 billion
CAGR of 8.1% from 2023 to 2030
Base year for estimation
2018 - 2030
2023 - 2030
Revenue in USD million/billion and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, end use, region
China; Japan; India; South Korea; Australia; Thailand; New Zealand; Singapore; Vietnam
Key companies profiled
Wipro; ZOE Limited; Vocalis Health; DarwinAI; Biocogniv Inc.; Laipac Technology Inc.; Gauss Surgical, Inc.; Oxford Immune Algorithmics Ltd; F. Hoffmann-La Roche Ltd.; QIAGEN; Danaher; Beckman Coulter, Inc.; Radiometer Medical ApS; HemoCue AB; BD (Becton, Dickinson and Company); BIOMÉRIEUX; Abbott; Siemens Healthcare GmbH; Zoetis Services LLC; Abaxis; Instrumentation Laboratory Company; Nova Biomedical; Trividia Health, Inc.; Quidel Corporation; Trinity Biotech; SEKISUI Diagnostics; Orasure Technologies, Inc.; Nipro Europe Group Companies; Spectral Medical Inc.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the Asia Pacific point of care diagnostics market report on the basis of product, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Clostridium Difficile POC
Pneumonia or Streptococcus Associated Infections
Respiratory Syncytial Virus (RSV) POC
TB and Drug-resistant TB POC
Other Infectious Diseases
Thyroid Stimulating Hormone
Primary Care Systems
Decentralized Clinical Chemistry
Drug Abuse Testing
End Use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmacy & Retail Clinics
Urgent Care Clinic
Assisted Living Healthcare Facilities
Regional Outlook (Revenue, USD Million, 2018 - 2030)
b. The Asia Pacific point of care diagnostics market size was estimated at USD 8.17 billion in 2022 and is expected to reach USD 9.04 million in 2023.
b. The Asia Pacific point of care diagnostics market is expected to grow at a compound annual growth rate of 8.1% from 2023 to 2030 to reach USD 15.61 million by 2030.
b. The glucose testing segment dominated the Asia Pacific point of care diagnostics market with a share of 21.4% in 2022. The growing popularity of wearable or portable glucose meters due to their speed, easy operation, and less cost is anticipated to drive the demand for glucose testing.
b. Some key players operating in the Asia Pacific point of care diagnostics market include Alere Inc., Siemens Healthcare, Roche Diagnostics, Danaher Corporation, bioMerieux, and Abbott Laboratories
b. Key factors that are driving the Asia Pacific point of care diagnostics market growth include robust government initiatives, the presence of favorable regulations, and the advent of next-generation point of care diagnostics technologies.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."